Skip to main content

Table 1 Published studies that favor combination therapy for in-hospital patients with CAP

From: Combination antibiotic therapy for community-acquired pneumonia

Author Year Cohort Site Outcome Study design
Gleason et al. [16] 1999 Patients aged ≥ 65 years with CAP Ward Lower 30-day mortality with β-lactam plus macrolide Multicenter, retrospective
Dudas et al. [17] 2000 CAP Ward Lower mortality with β-lactam plus macrolide and reduced LOS Multicenter, prospective
Waterer et al. [19] 2001 Pneumococcal bacteremia Ward Lower hospital mortality with combination Multicenter, retrospective
Brown et al. [21] 2003 CAP Ward Lower 30-day mortality with β-lactam plus macrolide Multicenter, retrospective
Martínez et al. [20] 2003 Pneumococcal bacteremia Ward Lower in-hospital mortality with β-lactam plus macrolide Monocenter, retrospective
Baddour et al. [22] 2004 Pneumococcal bacteremia Ward ICU Lower 14-day mortality with combination Multicenter, prospective
Weiss et al. [5] 2004 Pneumococcal bacteremia Ward Lower mortality with combination Monocenter, retrospective
García-Vázquez et al. [23] 2005 CAP Ward Lower mortality with β-lactam plus macrolide Multicenter, prospective
Mortensen et al. [24] 2006 CAP Ward ICU Lower 30-day mortality with β-lactam plus other than FQ Multicenter, retrospective
Rodríguez et al. [25] 2007 CAP ICU Lower 28-day mortality with combination Multicenter, retrospective
Metersky et al. [26] 2007 Pneumococcal bacteremia Ward Lower 30-day mortality with β-lactam plus macrolide Multicenter, retrospective
Restrepo et al. [27] 2009 Severe sepsis pneumonia Ward Lower 30- and 90-day mortalities with combination plus macrolide Multicenter, retrospective
Tessmer et al. [28] 2009 CAP Ward Lower 14- and 30-day mortalities with β-lactam plus macrolide Multicenter, retrospective
Martín-Loeches et al. [29] 2010 Intubated CAP ICU Lower ICU mortality IDSA/ATS combination plus macrolide Multicenter, prospective